PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 6487293

A new method of parameter estimation from progress curves.

H G Holzhütter·W Henke
View original source ↗Export metadata ↓

Abstract

A mathematical procedure is presented which permits kinetic parameters to be determined from progress curve data. The method is applicable to any kind of enzymatic reaction which can be described by a single rate equation. A general criterion is derived to check the accuracy of the method. An application to a simulated 2-substrate reaction is given.

Explore related subjects

Half-LifeKineticsModels, BiologicalStatistics as TopicJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H G Holzhütter, W Henke. 1984. A new method of parameter estimation from progress curves.. https://pubmed.ncbi.nlm.nih.gov/6487293/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1995

Radiation dosimetry for bolus administration of oxygen-15-water.

UNLABELLED: We describe the development of a biokinetic model which permits an estimation of organ activities and the dosimetry of a bolus of 15O-water. The aim of this study was to estimate time-activity functions and deduce the cumulated activities in different organs so that the radiation absorbed dose values can be estimated. METHODS: The model we used includes the right heart chambers, lungs, left heart chamber, brain, liver, kidneys, muscles, gastrointestinal tract and the remainder of the body. Activity in an organ will decay by physical decay with the decay constant, lambda, and can diffuse in the organ. An exception is the heart, where blood is ejected from the heart chambers. Depending on the location of the organ in relation to the blood sampling point, organ activities can be calculated by convolution or deconvolution. RESULTS: The radiation absorbed dose values were estimated and an effective dose equivalent HE of 1.16 microSv/MBq (4.32 mrem/mCi) as well as an effective dose E of 1.15 microSv/MBq (4.25 mrem/mCi) were calculated. The cumulated activities in select organs measured by PET gave good agreement with the values calculated by this model. CONCLUSION: The values of effective dose equivalent and effective dose for bolus administration of 15O-water calculated from the absorbed doses estimated by the proposed kinetic model are almost three times higher than those previously published. A total of 8700 MBq (235 mCi) of 15O-water can be administered if an effective dose of 10 mSv (1 rem) is accepted.

Half-Life↗
PubMed1993

Alpha-fetoprotein half-life as a predictor of residual testicular tumor. Effect of the analytic strategy on test sensitivity and specificity.

BACKGROUND: Alpha-fetoprotein (AFP) serum values after orchiectomy for testicular cancer can be used to predict the residual disease status. However, the optimal strategy for postorchiectomy marker analysis has not been studied. This article evaluated different analytic methods in an effort to identify the approach that provided the greatest sensitivity and specificity for occult residual disease. METHODS: Statistical information on the AFP half-life (t1/2) derived from a clinical data set of 24 patients with AFP-secreting clinical Stage A testicular cancer and pathologically defined nodal status was incorporated into a mathematic model of postorchiectomy marker values as a function of residual tumor volume and time. The model was used to test the effect of various analytic strategies on detecting the residual tumor. The clinical data set then was analyzed to measure the effect of different analytic methods on the predictive value of the AFP t1/2. RESULTS: In the model, the AFP t1/2 calculated from a single set of serum measurements obtained from the initial serum t1/2 was a poor predictor of disease status in patients with up to 40% residual tumor volume. Determined by the sequential addition of serum values obtained at normal t1/2 intervals, the AFP t1/2 improved in sensitivity but required up to seven serial values (35 days) to detect an abnormal t1/2 in patients with 10% residual tumor. By contrast, changes in the most recent interval t1/2 relative to the initial calculated t1/2 predicted the disease status in patients with 10% residual tumor after four t1/2 (20 days) and in patients with 1% residual volume after 35 days. CONCLUSIONS: The use of this last strategy in the clinical data set improved both the sensitivity and specificity of the AFP t1/2 in predicting residual tumor relative to the other methods.

Half-Life↗